A rise in the concentrations of these fatty acids in the blood should therefore be an indication of protection against cardiovascular risk. In the group receiving EPO the initial concentration for the sum of these four essential fatty acids was 338 mg/l and the final concentration 422 mg/I. In the group receiving olive oil, possibly because they were on 
The absolute numbers of CD4+ cells were normal on both occasions.
This patient had arterial tenderness, raised ESR, headaches, visual symptoms, and a prompt resolution of clinical features with steroids, thus fulfilling all the diagnostic criteria for giant cell arteritis.2 Although visual symptoms are fairly common in giant cell arteritis, they usually result from arteritis of the posterior ciliary or the ophthalmic artery.' Uveitis is much less common and to our knowledge this is the first report of acute anterior and posterior uveitis occurring as a presenting feature of temporal arteritis. The only other case reported with a similar association is that of subacute uveitic glaucoma, in which giant cell arteritis was shown by temporal artery biopsy, though the patient did not A rise in the concentrations of these fatty acids in the blood should therefore be an indication of protection against cardiovascular risk. In the group receiving EPO the initial concentration for the sum of these four essential fatty acids was 338 mg/l and the final concentration 422 mg/I. In the group receiving olive oil, possibly because they were on average 12 years younger than the EPO group, the initial value was more favourable at 371 mg/I. But the rise was much smaller, to only 383 mg/i. On Dr Horrobin stresses interesting and possibly important aspects. The effects of evening primrose oil (EPO) in rheumatoid arthritis may be slow in onset and first appear later than the observation period (12 weeks) in our study.
From an ethical and practical point of view, however, at least in the Finnish rheumatic population, it was not possible to continue the study longer with ineffective treatment. On the other hand, the trial was long enough to cause changes in serum fatty acid composition.
The conclusion presented by Dr Horrobin that EPO and olive oil may be as good as non-steroidal anti-inflammatory drugs at controlling symptoms of rheumatoid arthritis is interesting, but is premature and too speculative.
We agree that the changes caused by EPO in serum fatty acid composition are small, maximally about 23% increase in arachidonic acid and about 42% decrease in eicosapentaenoic acid percentage share. Low concentrations of polyunsaturated fatty acids have been suggested to indicate increased risk for cardiovascular disease in the two studies referred to by Dr Horrobin. Our point of view was, however, to stress the precursor fatty acids balance for thromboxane production.
Dr Horrobin refers at the end of his letter to our discussion on published reports of the total cholesterol and high density lipoprotein (HDL)-cholesterol lowering effect of polyunsaturated fatty acids. Contrary to his interpretation we did not discuss EPO because it had no effect either on total or on HDL-cholesterol.
In 
